报价延迟最少15分钟:2026/04/26 01:18 EDT
常规时段
|
|
|
|
|
||||||||||||
|
|
|
|
|
7.29 
|
|
|
| 价值评估 |
|
盈利(现时/预测)
-1.67/3.64
|
|
企业价值
185.50M
|
| 资产负债 |
|
每股账面净值
1.20
|
| 现金流量 |
|
现金流量率
--
|
| 损益表 |
|
收益
0
|
|
每股收益
0.06
|
|
同行比较
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
同行比较之报价最少15分钟延迟 (夜盘时段除外)
|
业务概览
|
|||
| Unicycive Therapeutics Inc is a clinical-stage biotechnology company focused on identifying, developing, and commercializing therapies to address unmet medical needs, with a primary focus on kidney disease. The company is advancing two keyproduct candidates: oxylanthanum carbonate (OLC), a phosphate binder for the treatment of hyperphosphatemia in chronic kidney disease patients on dialysis, and UNI-494, a drug candidate for the treatment of acute kidney injury. |
